دورية أكاديمية
Critically evaluated key points on hereditary medullary thyroid carcinoma.
| العنوان: | Critically evaluated key points on hereditary medullary thyroid carcinoma. |
|---|---|
| المؤلفون: | Zhang D; Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China., Liang N; Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China., Sun H; Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China., Frattini F; Division of Surgery, Istituto Auxologico Italiano IRCCS (Istituto di Ricovero e Cura a Carattere Scientifco), Milan, Italy., Sui C; Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China., Yang M; Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China., Wang H; Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, China., Dionigi G; Division of Surgery, Istituto Auxologico Italiano IRCCS (Istituto di Ricovero e Cura a Carattere Scientifco), Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. |
| المصدر: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jun 11; Vol. 15, pp. 1412942. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Thyroid Neoplasms*/genetics , Thyroid Neoplasms*/diagnosis , Thyroid Neoplasms*/pathology , Thyroid Neoplasms*/therapy , Proto-Oncogene Mas* , Carcinoma, Medullary*/genetics , Carcinoma, Medullary*/congenital , Carcinoma, Medullary*/diagnosis , Carcinoma, Medullary*/pathology , Carcinoma, Medullary*/therapy , Multiple Endocrine Neoplasia Type 2a*/genetics , Multiple Endocrine Neoplasia Type 2a*/diagnosis , Multiple Endocrine Neoplasia Type 2a*/pathology , Multiple Endocrine Neoplasia Type 2a*/therapy, Humans ; Proto-Oncogene Proteins c-ret/genetics ; Thyroidectomy ; Mutation ; Calcitonin/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinoma, Neuroendocrine/genetics ; Carcinoma, Neuroendocrine/diagnosis ; Carcinoma, Neuroendocrine/pathology |
| مستخلص: | Medullary thyroid carcinoma (MTC) accounts for only 3% of all thyroid carcinomas: 75% as sporadic MTC (sMTC) and 25% as hereditary MTC (hMTC) in the context of multiple endocrine neoplasia type 2 (MEN2). Early diagnosis is possible by determining the tumour marker calcitonin (Ctn) when clarifying nodular goitre and by detecting the mutation in the proto-oncogene RET in the MEN2 families. If the Ctn level is only slightly elevated, up to 30 pg/ml in women and up to 60 pg/ml in men, follow-up checks are advisable. At higher levels, surgery should be considered; at a level of > 100 pg/ml, surgery is always advisable. The treatment of choice is total thyroidectomy, possibly with central lymphadenectomy. In the early stage, cure is possible with adequate surgery; in the late stage, treatment with tyrosine kinase inhibitors is an option. RET A mutation analysis should be performed on all patients with MTC. During follow-up, a biochemical distinction is made between: healed (Ctn not measurably low), biochemically incomplete (Ctn increased without tumour detection) and structural tumour detection (metastases on imaging). After MTC surgery, the following results should be available for classification in follow-up care: (i) histology, Ctn immunohistology if necessary, (ii) classification according to the pTNM scheme, (iii) the result of the RET analysis for categorisation into the hereditary or sporadic variant and (iiii) the postoperative Ctn value. Tumour progression is determined by assessing the Ctn doubling time and the RECIST criteria on imaging. In most cases, "active surveillance" is possible. In the case of progression and symptoms, the following applies: local (palliative surgery, radiotherapy) before systemic (tyrosine kinase inhibitors). Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Zhang, Liang, Sun, Frattini, Sui, Yang, Wang and Dionigi.) |
| References: | J Clin Endocrinol Metab. 2010 Jun;95(6):2655-63. (PMID: 20339026) Endocr Relat Cancer. 2018 Mar;25(3):217-231. (PMID: 29298817) Front Oncol. 2024 Jan 29;14:1278816. (PMID: 38347847) Thyroid Res. 2013 Mar 14;6 Suppl 1:S2. (PMID: 23514432) Clin Endocrinol (Oxf). 2015 Dec;83(6):938-42. (PMID: 25376110) Front Endocrinol (Lausanne). 2023 Mar 31;14:1153248. (PMID: 37065753) Lancet Diabetes Endocrinol. 2016 Jan;4(1):64-71. (PMID: 26608066) Endocr Relat Cancer. 2024 Mar 18;31(5):. (PMID: 38376827) Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):158-62. (PMID: 18327036) Histopathology. 2024 May;84(6):947-959. (PMID: 38253940) Clin Endocrinol (Oxf). 2024 May;100(5):468-476. (PMID: 38472743) Clin Chem. 2017 Sep;63(9):1489-1496. (PMID: 28687633) Eur Thyroid J. 2013 Jan;1(4):216-31. (PMID: 24783025) Eur Thyroid J. 2013 Mar;2(1):49-56. (PMID: 24783038) Cancers (Basel). 2019 Oct 09;11(10):. (PMID: 31600997) Orphanet J Rare Dis. 2015 Mar 01;10:25. (PMID: 25887804) Eur J Endocrinol. 2023 Jan 10;188(1):. (PMID: 36651167) Front Endocrinol (Lausanne). 2022 Mar 08;13:861869. (PMID: 35350101) Cancer. 2000 Apr 15;88(8):1909-15. (PMID: 10760769) Front Endocrinol (Lausanne). 2022 Jul 11;13:875875. (PMID: 35898450) Front Endocrinol (Lausanne). 2021 Oct 13;12:754565. (PMID: 34721303) Langenbecks Arch Surg. 2013 Mar;398(3):347-75. (PMID: 23456424) Ann Oncol. 2019 Dec 1;30(12):1856-1883. (PMID: 31549998) Best Pract Res Clin Endocrinol Metab. 2023 Jan;37(1):101655. (PMID: 35422397) Dtsch Med Wochenschr. 2020 Aug;145(17):1245-1251. (PMID: 32634843) Ann Transl Med. 2022 Jun;10(12):709. (PMID: 35845523) Thyroid. 2015 Jun;25(6):567-610. (PMID: 25810047) Am J Surg. 2024 Feb 8;:. (PMID: 38365554) JAMA Otolaryngol Head Neck Surg. 2024 Mar 1;150(3):215-216. (PMID: 38270970) J Endocrinol Invest. 2021 Mar;44(3):587-597. (PMID: 32656666) |
| فهرسة مساهمة: | Keywords: CEA; calcitonin; diagnosis; hereditary; medullary thyroid carcinoma; men; pathology; thyroid |
| المشرفين على المادة: | 0 (Proto-Oncogene Mas) 0 (MAS1 protein, human) EC 2.7.10.1 (Proto-Oncogene Proteins c-ret) EC 2.7.10.1 (RET protein, human) 9007-12-9 (Calcitonin) 0 (Biomarkers, Tumor) |
| SCR Disease Name: | Familial medullary thyroid carcinoma; Thyroid cancer, medullary |
| تواريخ الأحداث: | Date Created: 20240626 Date Completed: 20240626 Latest Revision: 20240627 |
| رمز التحديث: | 20240627 |
| مُعرف محوري في PubMed: | PMC11197075 |
| DOI: | 10.3389/fendo.2024.1412942 |
| PMID: | 38919477 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-2392 |
|---|---|
| DOI: | 10.3389/fendo.2024.1412942 |